Jazz Pharmaceuticals JAZZ Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's stock issuance proceeds?
- Jazz Pharmaceuticals (JAZZ) reported stock issuance proceeds of $32.9M in Q1 2026.
- How has Jazz Pharmaceuticals's stock issuance proceeds changed year-over-year?
- Jazz Pharmaceuticals's stock issuance proceeds increased by 186.1% year-over-year, from $11.5M to $32.9M.
- What is the long-term trend for Jazz Pharmaceuticals's stock issuance proceeds?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's stock issuance proceeds has grown at a -5.5% compound annual growth rate (CAGR), from $135.26M to $107.86M.
- What does stock issuance proceeds mean?
- Cash received from selling company stock to investors or employees.
- How do you interpret stock issuance proceeds?
- An increase suggests successful capital raising or high employee participation in equity plans, while a decrease may indicate reduced reliance on equity financing.
- How does stock issuance proceeds compare across companies?
- Standard across all public companies; biotech firms often show higher volatility due to periodic secondary offerings.